argenx   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Breda Netherlands (2009)

Organization Overview

First Clinical Trial
2013
NCT01813539
First Marketed Drug
2021
efgartigimod
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

argenx | ARGENX BV | argenx BVBA | arGEN-X BVBA